nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—SCN5A—Riluzole—amyotrophic lateral sclerosis	0.708	1	CbGbCtD
Procainamide—SCN3A—spinal nerve—amyotrophic lateral sclerosis	0.016	0.117	CbGeAlD
Procainamide—Gastrointestinal tract irritation—Riluzole—amyotrophic lateral sclerosis	0.00992	0.105	CcSEcCtD
Procainamide—SCN11A—peripheral nervous system—amyotrophic lateral sclerosis	0.00853	0.0626	CbGeAlD
Procainamide—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.00819	0.0866	CcSEcCtD
Procainamide—BCHE—diaphragm—amyotrophic lateral sclerosis	0.00695	0.0509	CbGeAlD
Procainamide—SCN11A—nerve—amyotrophic lateral sclerosis	0.00665	0.0488	CbGeAlD
Procainamide—SCN8A—peripheral nervous system—amyotrophic lateral sclerosis	0.00646	0.0474	CbGeAlD
Procainamide—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0054	0.0571	CcSEcCtD
Procainamide—SCN8A—nerve—amyotrophic lateral sclerosis	0.00504	0.037	CbGeAlD
Procainamide—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00462	0.0489	CcSEcCtD
Procainamide—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00462	0.0489	CcSEcCtD
Procainamide—SCN10A—peripheral nervous system—amyotrophic lateral sclerosis	0.00432	0.0317	CbGeAlD
Procainamide—SCN8A—hindbrain—amyotrophic lateral sclerosis	0.00377	0.0277	CbGeAlD
Procainamide—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00354	0.0374	CcSEcCtD
Procainamide—SCN10A—nerve—amyotrophic lateral sclerosis	0.00337	0.0247	CbGeAlD
Procainamide—SCN1A—hindbrain—amyotrophic lateral sclerosis	0.00285	0.0209	CbGeAlD
Procainamide—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00271	0.0287	CcSEcCtD
Procainamide—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00264	0.028	CcSEcCtD
Procainamide—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00263	0.0278	CcSEcCtD
Procainamide—SCN2A—hindbrain—amyotrophic lateral sclerosis	0.00262	0.0192	CbGeAlD
Procainamide—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00251	0.0265	CcSEcCtD
Procainamide—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00244	0.0258	CcSEcCtD
Procainamide—SLC22A3—tongue—amyotrophic lateral sclerosis	0.00239	0.0175	CbGeAlD
Procainamide—SCN8A—brainstem—amyotrophic lateral sclerosis	0.00216	0.0159	CbGeAlD
Procainamide—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00213	0.0225	CcSEcCtD
Procainamide—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00208	0.022	CcSEcCtD
Procainamide—DNMT1—embryo—amyotrophic lateral sclerosis	0.00203	0.0149	CbGeAlD
Procainamide—Depression—Riluzole—amyotrophic lateral sclerosis	0.00198	0.0209	CcSEcCtD
Procainamide—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0195	CcSEcCtD
Procainamide—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00181	0.0191	CcSEcCtD
Procainamide—SCN11A—spinal cord—amyotrophic lateral sclerosis	0.00177	0.013	CbGeAlD
Procainamide—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00177	0.0187	CcSEcCtD
Procainamide—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00165	0.0174	CcSEcCtD
Procainamide—SCN1A—brainstem—amyotrophic lateral sclerosis	0.00164	0.012	CbGeAlD
Procainamide—Chills—Riluzole—amyotrophic lateral sclerosis	0.0016	0.0169	CcSEcCtD
Procainamide—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00152	0.016	CcSEcCtD
Procainamide—SCN2A—brainstem—amyotrophic lateral sclerosis	0.0015	0.011	CbGeAlD
Procainamide—SCN11A—nervous system—amyotrophic lateral sclerosis	0.0015	0.011	CbGeAlD
Procainamide—SCN11A—central nervous system—amyotrophic lateral sclerosis	0.00144	0.0106	CbGeAlD
Procainamide—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00144	0.0152	CcSEcCtD
Procainamide—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00141	0.015	CcSEcCtD
Procainamide—Malaise—Riluzole—amyotrophic lateral sclerosis	0.0014	0.0148	CcSEcCtD
Procainamide—SCN8A—spinal cord—amyotrophic lateral sclerosis	0.00135	0.00986	CbGeAlD
Procainamide—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0142	CcSEcCtD
Procainamide—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0139	CcSEcCtD
Procainamide—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0139	CcSEcCtD
Procainamide—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0138	CcSEcCtD
Procainamide—DNMT1—medulla oblongata—amyotrophic lateral sclerosis	0.0013	0.00953	CbGeAlD
Procainamide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00127	0.0135	CcSEcCtD
Procainamide—Shock—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0131	CcSEcCtD
Procainamide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0131	CcSEcCtD
Procainamide—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.0012	0.0127	CcSEcCtD
Procainamide—SCN9A—spinal cord—amyotrophic lateral sclerosis	0.00118	0.00867	CbGeAlD
Procainamide—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00118	0.0125	CcSEcCtD
Procainamide—DNMT1—spinal cord—amyotrophic lateral sclerosis	0.00116	0.0085	CbGeAlD
Procainamide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00115	0.0122	CcSEcCtD
Procainamide—SLC22A3—embryo—amyotrophic lateral sclerosis	0.00115	0.00841	CbGeAlD
Procainamide—SCN11A—brain—amyotrophic lateral sclerosis	0.00114	0.00838	CbGeAlD
Procainamide—SCN1A—medulla oblongata—amyotrophic lateral sclerosis	0.00114	0.00836	CbGeAlD
Procainamide—SCN8A—nervous system—amyotrophic lateral sclerosis	0.00113	0.00831	CbGeAlD
Procainamide—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0116	CcSEcCtD
Procainamide—SCN8A—central nervous system—amyotrophic lateral sclerosis	0.00109	0.008	CbGeAlD
Procainamide—SCN8A—cerebellum—amyotrophic lateral sclerosis	0.00107	0.00782	CbGeAlD
Procainamide—ACHE—medulla oblongata—amyotrophic lateral sclerosis	0.00106	0.00775	CbGeAlD
Procainamide—SCN2A—medulla oblongata—amyotrophic lateral sclerosis	0.00105	0.00768	CbGeAlD
Procainamide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00104	0.011	CcSEcCtD
Procainamide—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00103	0.0109	CcSEcCtD
Procainamide—SCN1A—spinal cord—amyotrophic lateral sclerosis	0.00102	0.00746	CbGeAlD
Procainamide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.001	0.0106	CcSEcCtD
Procainamide—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000999	0.0106	CcSEcCtD
Procainamide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000999	0.0106	CcSEcCtD
Procainamide—DNMT1—nervous system—amyotrophic lateral sclerosis	0.000977	0.00716	CbGeAlD
Procainamide—SCN7A—brain—amyotrophic lateral sclerosis	0.000972	0.00713	CbGeAlD
Procainamide—ACHE—spinal cord—amyotrophic lateral sclerosis	0.000942	0.00691	CbGeAlD
Procainamide—DNMT1—central nervous system—amyotrophic lateral sclerosis	0.000941	0.0069	CbGeAlD
Procainamide—SCN2A—spinal cord—amyotrophic lateral sclerosis	0.000933	0.00684	CbGeAlD
Procainamide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000931	0.00984	CcSEcCtD
Procainamide—SCN3A—medulla oblongata—amyotrophic lateral sclerosis	0.00092	0.00675	CbGeAlD
Procainamide—DNMT1—cerebellum—amyotrophic lateral sclerosis	0.000919	0.00674	CbGeAlD
Procainamide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000906	0.00958	CcSEcCtD
Procainamide—SCN10A—spinal cord—amyotrophic lateral sclerosis	0.0009	0.0066	CbGeAlD
Procainamide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000894	0.00945	CcSEcCtD
Procainamide—SCN4A—nervous system—amyotrophic lateral sclerosis	0.000889	0.00652	CbGeAlD
Procainamide—SCN8A—brain—amyotrophic lateral sclerosis	0.000866	0.00635	CbGeAlD
Procainamide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000864	0.00914	CcSEcCtD
Procainamide—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000861	0.00631	CbGeAlD
Procainamide—SCN1A—nervous system—amyotrophic lateral sclerosis	0.000857	0.00628	CbGeAlD
Procainamide—SCN4A—central nervous system—amyotrophic lateral sclerosis	0.000856	0.00627	CbGeAlD
Procainamide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000835	0.00883	CcSEcCtD
Procainamide—SCN1A—central nervous system—amyotrophic lateral sclerosis	0.000825	0.00605	CbGeAlD
Procainamide—SCN3A—spinal cord—amyotrophic lateral sclerosis	0.00082	0.00602	CbGeAlD
Procainamide—SCN1A—cerebellum—amyotrophic lateral sclerosis	0.000806	0.00591	CbGeAlD
Procainamide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000803	0.00849	CcSEcCtD
Procainamide—SCN2A—nervous system—amyotrophic lateral sclerosis	0.000786	0.00577	CbGeAlD
Procainamide—SCN9A—brain—amyotrophic lateral sclerosis	0.000761	0.00558	CbGeAlD
Procainamide—SCN10A—nervous system—amyotrophic lateral sclerosis	0.000758	0.00556	CbGeAlD
Procainamide—SCN2A—central nervous system—amyotrophic lateral sclerosis	0.000757	0.00555	CbGeAlD
Procainamide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00075	0.00793	CcSEcCtD
Procainamide—ACHE—cerebellum—amyotrophic lateral sclerosis	0.000747	0.00548	CbGeAlD
Procainamide—DNMT1—brain—amyotrophic lateral sclerosis	0.000747	0.00548	CbGeAlD
Procainamide—BCHE—brainstem—amyotrophic lateral sclerosis	0.000744	0.00546	CbGeAlD
Procainamide—SCN2A—cerebellum—amyotrophic lateral sclerosis	0.00074	0.00543	CbGeAlD
Procainamide—SCN10A—central nervous system—amyotrophic lateral sclerosis	0.00073	0.00535	CbGeAlD
Procainamide—SLC22A4—spinal cord—amyotrophic lateral sclerosis	0.000718	0.00527	CbGeAlD
Procainamide—SCN3A—nervous system—amyotrophic lateral sclerosis	0.000691	0.00507	CbGeAlD
Procainamide—SCN5A—nervous system—amyotrophic lateral sclerosis	0.000689	0.00505	CbGeAlD
Procainamide—SCN4A—brain—amyotrophic lateral sclerosis	0.000679	0.00498	CbGeAlD
Procainamide—SCN3A—central nervous system—amyotrophic lateral sclerosis	0.000665	0.00488	CbGeAlD
Procainamide—SCN5A—central nervous system—amyotrophic lateral sclerosis	0.000664	0.00487	CbGeAlD
Procainamide—SCN1A—brain—amyotrophic lateral sclerosis	0.000655	0.0048	CbGeAlD
Procainamide—SCN3A—cerebellum—amyotrophic lateral sclerosis	0.00065	0.00477	CbGeAlD
Procainamide—ACHE—brain—amyotrophic lateral sclerosis	0.000607	0.00445	CbGeAlD
Procainamide—SCN2A—brain—amyotrophic lateral sclerosis	0.000601	0.00441	CbGeAlD
Procainamide—CHRM2—nervous system—amyotrophic lateral sclerosis	0.000587	0.0043	CbGeAlD
Procainamide—SCN10A—brain—amyotrophic lateral sclerosis	0.00058	0.00425	CbGeAlD
Procainamide—SLC22A1—nervous system—amyotrophic lateral sclerosis	0.000576	0.00423	CbGeAlD
Procainamide—SLC22A4—cerebellum—amyotrophic lateral sclerosis	0.000569	0.00418	CbGeAlD
Procainamide—CHRM2—central nervous system—amyotrophic lateral sclerosis	0.000565	0.00414	CbGeAlD
Procainamide—SLC22A1—central nervous system—amyotrophic lateral sclerosis	0.000555	0.00407	CbGeAlD
Procainamide—SLC22A3—nervous system—amyotrophic lateral sclerosis	0.000551	0.00404	CbGeAlD
Procainamide—SLC22A5—medulla oblongata—amyotrophic lateral sclerosis	0.000533	0.00391	CbGeAlD
Procainamide—SLC22A3—central nervous system—amyotrophic lateral sclerosis	0.00053	0.00389	CbGeAlD
Procainamide—SCN3A—brain—amyotrophic lateral sclerosis	0.000528	0.00387	CbGeAlD
Procainamide—SCN5A—brain—amyotrophic lateral sclerosis	0.000527	0.00386	CbGeAlD
Procainamide—BCHE—medulla oblongata—amyotrophic lateral sclerosis	0.000519	0.00381	CbGeAlD
Procainamide—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000493	0.00362	CbGeAlD
Procainamide—SLC22A5—spinal cord—amyotrophic lateral sclerosis	0.000475	0.00349	CbGeAlD
Procainamide—BCHE—spinal cord—amyotrophic lateral sclerosis	0.000463	0.00339	CbGeAlD
Procainamide—SLC22A4—brain—amyotrophic lateral sclerosis	0.000463	0.00339	CbGeAlD
Procainamide—CHRM2—brain—amyotrophic lateral sclerosis	0.000448	0.00329	CbGeAlD
Procainamide—SLC22A1—brain—amyotrophic lateral sclerosis	0.00044	0.00323	CbGeAlD
Procainamide—SLC22A3—brain—amyotrophic lateral sclerosis	0.000421	0.00309	CbGeAlD
Procainamide—BCHE—nervous system—amyotrophic lateral sclerosis	0.00039	0.00286	CbGeAlD
Procainamide—SLC22A5—cerebellum—amyotrophic lateral sclerosis	0.000377	0.00276	CbGeAlD
Procainamide—BCHE—central nervous system—amyotrophic lateral sclerosis	0.000376	0.00275	CbGeAlD
Procainamide—BCHE—cerebellum—amyotrophic lateral sclerosis	0.000367	0.00269	CbGeAlD
Procainamide—SLC22A5—brain—amyotrophic lateral sclerosis	0.000306	0.00224	CbGeAlD
Procainamide—BCHE—brain—amyotrophic lateral sclerosis	0.000298	0.00219	CbGeAlD
Procainamide—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000258	0.0019	CbGeAlD
Procainamide—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000249	0.00182	CbGeAlD
Procainamide—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000243	0.00178	CbGeAlD
Procainamide—CYP2D6—brain—amyotrophic lateral sclerosis	0.000198	0.00145	CbGeAlD
Procainamide—SLC22A2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000146	0.0024	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000146	0.0024	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000146	0.0024	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000145	0.00239	CbGpPWpGaD
Procainamide—DNMT1—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	0.000143	0.00236	CbGpPWpGaD
Procainamide—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000143	0.00236	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00014	0.00231	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00014	0.00231	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—RARA—amyotrophic lateral sclerosis	0.00014	0.0023	CbGpPWpGaD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000139	0.00229	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000137	0.00226	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000136	0.00224	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000136	0.00224	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000136	0.00224	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000136	0.00224	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	0.000135	0.00222	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000135	0.00222	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000133	0.00219	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000131	0.00216	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00013	0.00214	CbGpPWpGaD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00013	0.00213	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000127	0.00209	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000127	0.00209	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000127	0.00209	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000125	0.00206	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000125	0.00206	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.000125	0.00206	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000125	0.00206	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000122	0.00202	CbGpPWpGaD
Procainamide—ACHE—Peptide hormone metabolism—IGF1—amyotrophic lateral sclerosis	0.000122	0.00201	CbGpPWpGaD
Procainamide—ACHE—Phospholipid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000122	0.002	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000121	0.002	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00012	0.00198	CbGpPWpGaD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000118	0.00195	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000117	0.00192	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000113	0.00186	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000113	0.00186	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000112	0.00185	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000112	0.00185	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000112	0.00184	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000112	0.00184	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.000112	0.00184	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000112	0.00184	CbGpPWpGaD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00011	0.00182	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00011	0.00181	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000109	0.0018	CbGpPWpGaD
Procainamide—BCHE—Peptide hormone metabolism—IGF1—amyotrophic lateral sclerosis	0.000109	0.00179	CbGpPWpGaD
Procainamide—BCHE—Phospholipid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000109	0.00179	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000108	0.00178	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000108	0.00178	CbGpPWpGaD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000105	0.00174	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000105	0.00172	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000104	0.00172	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000104	0.00172	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.000103	0.0017	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000102	0.00168	CbGpPWpGaD
Procainamide—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000102	0.00168	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	9.96e-05	0.00164	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—VAPA—amyotrophic lateral sclerosis	9.88e-05	0.00163	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	9.82e-05	0.00162	CbGpPWpGaD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	9.82e-05	0.00162	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—MMP9—amyotrophic lateral sclerosis	9.75e-05	0.00161	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	9.58e-05	0.00158	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	9.58e-05	0.00158	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	9.55e-05	0.00157	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	9.55e-05	0.00157	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	9.38e-05	0.00155	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	9.33e-05	0.00154	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	9.28e-05	0.00153	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	9.19e-05	0.00151	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.19e-05	0.00151	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	8.75e-05	0.00144	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	8.69e-05	0.00143	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—MMP9—amyotrophic lateral sclerosis	8.69e-05	0.00143	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	8.67e-05	0.00143	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—FIG4—amyotrophic lateral sclerosis	8.64e-05	0.00142	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	8.54e-05	0.00141	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	8.51e-05	0.0014	CbGpPWpGaD
Procainamide—ACHE—Metabolism—VAPB—amyotrophic lateral sclerosis	8.5e-05	0.0014	CbGpPWpGaD
Procainamide—ACHE—Metabolism—TPK1—amyotrophic lateral sclerosis	8.5e-05	0.0014	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—MMP9—amyotrophic lateral sclerosis	7.95e-05	0.00131	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.93e-05	0.00131	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	7.85e-05	0.00129	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—DAO—amyotrophic lateral sclerosis	7.81e-05	0.00129	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	7.8e-05	0.00128	CbGpPWpGaD
Procainamide—ACHE—Metabolism—VAPA—amyotrophic lateral sclerosis	7.78e-05	0.00128	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	7.73e-05	0.00127	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	7.6e-05	0.00125	CbGpPWpGaD
Procainamide—BCHE—Metabolism—VAPB—amyotrophic lateral sclerosis	7.59e-05	0.00125	CbGpPWpGaD
Procainamide—BCHE—Metabolism—TPK1—amyotrophic lateral sclerosis	7.59e-05	0.00125	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	7.37e-05	0.00121	CbGpPWpGaD
Procainamide—ACHE—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.23e-05	0.00119	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	7.13e-05	0.00118	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.07e-05	0.00117	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	7.07e-05	0.00116	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	6.96e-05	0.00115	CbGpPWpGaD
Procainamide—BCHE—Metabolism—VAPA—amyotrophic lateral sclerosis	6.94e-05	0.00114	CbGpPWpGaD
Procainamide—ACHE—Metabolism—FIG4—amyotrophic lateral sclerosis	6.8e-05	0.00112	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—VAPB—amyotrophic lateral sclerosis	6.78e-05	0.00112	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TPK1—amyotrophic lateral sclerosis	6.78e-05	0.00112	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	6.62e-05	0.00109	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	6.59e-05	0.00108	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	6.58e-05	0.00108	CbGpPWpGaD
Procainamide—BCHE—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.45e-05	0.00106	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	6.45e-05	0.00106	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—MMP9—amyotrophic lateral sclerosis	6.43e-05	0.00106	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	6.38e-05	0.00105	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.32e-05	0.00104	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.32e-05	0.00104	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	6.25e-05	0.00103	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	6.2e-05	0.00102	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—VAPA—amyotrophic lateral sclerosis	6.2e-05	0.00102	CbGpPWpGaD
Procainamide—ACHE—Metabolism—DAO—amyotrophic lateral sclerosis	6.15e-05	0.00101	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—MMP9—amyotrophic lateral sclerosis	6.15e-05	0.00101	CbGpPWpGaD
Procainamide—BCHE—Metabolism—FIG4—amyotrophic lateral sclerosis	6.07e-05	0.000999	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	6.01e-05	0.00099	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	6.01e-05	0.00099	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PLB1—amyotrophic lateral sclerosis	5.92e-05	0.000975	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—MMP9—amyotrophic lateral sclerosis	5.9e-05	0.000973	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—MMP9—amyotrophic lateral sclerosis	5.9e-05	0.000973	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—VAPA—amyotrophic lateral sclerosis	5.78e-05	0.000952	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.77e-05	0.000951	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.76e-05	0.000949	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—MMP9—amyotrophic lateral sclerosis	5.69e-05	0.000938	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—MMP9—amyotrophic lateral sclerosis	5.69e-05	0.000938	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	5.67e-05	0.000934	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	5.6e-05	0.000922	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	5.6e-05	0.000922	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	5.57e-05	0.000917	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.52e-05	0.000909	CbGpPWpGaD
Procainamide—BCHE—Metabolism—DAO—amyotrophic lateral sclerosis	5.49e-05	0.000904	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GSR—amyotrophic lateral sclerosis	5.46e-05	0.0009	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	5.44e-05	0.000897	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—FIG4—amyotrophic lateral sclerosis	5.42e-05	0.000892	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.37e-05	0.000885	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.35e-05	0.000882	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.3e-05	0.000873	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.3e-05	0.000873	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	5.29e-05	0.000871	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.11e-05	0.000842	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.11e-05	0.000842	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	5.09e-05	0.000839	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.05e-05	0.000832	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	4.99e-05	0.000822	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	4.91e-05	0.000809	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—DAO—amyotrophic lateral sclerosis	4.9e-05	0.000807	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	4.86e-05	0.0008	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	4.77e-05	0.000786	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PLB1—amyotrophic lateral sclerosis	4.66e-05	0.000768	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.59e-05	0.000755	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—DAO—amyotrophic lateral sclerosis	4.57e-05	0.000752	CbGpPWpGaD
Procainamide—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.55e-05	0.00075	CbGpPWpGaD
Procainamide—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.49e-05	0.00074	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CHAT—amyotrophic lateral sclerosis	4.49e-05	0.000739	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.39e-05	0.000722	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GSR—amyotrophic lateral sclerosis	4.3e-05	0.000708	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.21e-05	0.000694	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.21e-05	0.000694	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.17e-05	0.000686	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PLB1—amyotrophic lateral sclerosis	4.16e-05	0.000685	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	4.12e-05	0.000678	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.06e-05	0.000669	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.06e-05	0.000669	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MMP9—amyotrophic lateral sclerosis	4e-05	0.000659	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.94e-05	0.000649	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	3.92e-05	0.000646	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.92e-05	0.000645	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GSR—amyotrophic lateral sclerosis	3.84e-05	0.000632	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	3.79e-05	0.000625	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.78e-05	0.000623	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.78e-05	0.000623	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	3.74e-05	0.000616	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.71e-05	0.000612	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.65e-05	0.000601	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.65e-05	0.000601	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.59e-05	0.000592	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CHAT—amyotrophic lateral sclerosis	3.53e-05	0.000582	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.49e-05	0.000576	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	3.49e-05	0.000575	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	3.49e-05	0.000575	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.46e-05	0.00057	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSR—amyotrophic lateral sclerosis	3.43e-05	0.000564	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.4e-05	0.000559	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	3.33e-05	0.000548	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.22e-05	0.000531	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSR—amyotrophic lateral sclerosis	3.19e-05	0.000526	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.19e-05	0.000526	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CHAT—amyotrophic lateral sclerosis	3.15e-05	0.000519	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.15e-05	0.000518	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.97e-05	0.000489	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	2.89e-05	0.000476	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.87e-05	0.000474	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.86e-05	0.000471	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.81e-05	0.000464	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.79e-05	0.000459	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.65e-05	0.000436	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.62e-05	0.000432	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.57e-05	0.000423	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.52e-05	0.000415	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.49e-05	0.00041	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.41e-05	0.000397	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.36e-05	0.000389	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	2.3e-05	0.000379	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.28e-05	0.000376	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.22e-05	0.000365	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.21e-05	0.000364	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	2.05e-05	0.000338	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.03e-05	0.000334	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.01e-05	0.00033	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.97e-05	0.000324	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.91e-05	0.000315	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.9e-05	0.000313	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—APOE—amyotrophic lateral sclerosis	1.82e-05	0.0003	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.76e-05	0.000291	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.74e-05	0.000287	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.69e-05	0.000279	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.68e-05	0.000276	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.63e-05	0.000269	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.56e-05	0.000256	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.51e-05	0.000249	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.48e-05	0.000244	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.45e-05	0.000239	CbGpPWpGaD
Procainamide—ACHE—Metabolism—APOE—amyotrophic lateral sclerosis	1.44e-05	0.000236	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.41e-05	0.000232	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.39e-05	0.000229	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.38e-05	0.000227	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.3e-05	0.000213	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.29e-05	0.000213	CbGpPWpGaD
Procainamide—BCHE—Metabolism—APOE—amyotrophic lateral sclerosis	1.28e-05	0.000211	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.25e-05	0.000206	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.23e-05	0.000203	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—APOE—amyotrophic lateral sclerosis	1.14e-05	0.000188	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.07e-05	0.000176	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.05e-05	0.000174	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.91e-06	0.000163	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.83e-06	0.000162	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.77e-06	0.000145	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.76e-06	0.000144	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.15e-06	0.000134	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.83e-06	0.000129	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.79e-06	0.000128	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.3e-06	0.00012	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.15e-06	0.000118	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.74e-06	0.000111	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	5.89e-06	9.7e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.19e-06	8.54e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.9e-06	8.07e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.4e-06	7.25e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.03e-06	6.64e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.32e-06	5.48e-05	CbGpPWpGaD
